busulfan has been researched along with Acute Disease in 150 studies
Acute Disease: Disease having a short and relatively severe course.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To reduce the incidence of graft-versus-host disease (GVHD), we added Thymoglobulin (THY) to dose-adjusted oral busulfan plus cyclophosphamide (targeted BUCY)." | 9.12 | Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. ( Anasetti, C; Appelbaum, FR; Boeckh, M; Deeg, HJ; Doney, KC; Flowers, ME; Hansen, JA; Heimfeld, S; Kiem, HP; Martin, PJ; McCune, JS; Myerson, D; Nash, RA; O'Donnell, PV; Radich, JP; Sandmaier, BM; Scott, BL; Sorror, ML; Storb, R; Storer, BE; Warren, EH; Witherspoon, RP; Woolfrey, A, 2006) |
| " From 1974 to 1986 we treated 20 symptomatic ET patients with microvascular circulation disturbances including erythromelalgia (N = 18), atypical or typical transient ischemic attacks (N = 6), or acute coronary ischemic syndrome (N = 3) with aspirin and one course of busulfan." | 9.09 | Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia. ( Michiels, JJ, 1999) |
| "In order to strengthen the anti-leukemia effect, we developed a new conditioning regimen with high dose busulfan, VP-16 and ACNU (BVA) for cytoreduction before stem cell transplantation." | 9.07 | [High-dose busulfan, VP-16 and ACNU therapy with stem cell transplantation for the treatment of children with acute leukemia]. ( Fujioka, K; Funabiki, T; Ikuta, K; Kai, S; Kajigaya, Y; Matsuyama, S; Sakai, H; Sekiguchi, H; Sumita, H; Takahashi, H, 1993) |
| " We therefore assessed 83 patients (age, 16-70 years): 68 with acute leukemia (including 34 in remission and 34 with refractory disease) and 15 patients with myelodysplastic syndrome, in HCT trials using RIC with busulfan, fludarabine, and antithymocyte globulin." | 7.77 | Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. ( Hwang, HJ; Jeon, M; Jung, AR; Kang, YA; Kim, DY; Kim, SH; Lee, JH; Lee, KH; Lee, YS; Seol, M; Shin, HJ; Yun, SC, 2011) |
| "To analyze the results of idarubicin (IDA)- versus etoposide (VP16)-intensified myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation (allo-SCT) for high-risk acute leukemia." | 7.75 | A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia. ( Chen, ZC; Li, L; Li, QB; Xia, LH; You, Y; Zou, P, 2009) |
| "We retrospectively evaluated early and long-term complications of an intensified conditioning regimen consisting of busulfan and etoposide in combination with either nimustine hydrochloride (ACNU) (BVA regimen, n = 18) or melphalan (BVL regimen, n = 34) in 52 children with acute leukemia or non-Hodgkin's lymphoma." | 7.74 | Long-term follow-up of busulfan, etoposide, and nimustine hydrochloride (ACNU) or melphalan as conditioning regimens for childhood acute leukemia and lymphoma. ( Fujioka, K; Funabiki, T; Goto, H; Goto, S; Hanzawa, N; Ikuta, K; Izaki, S; Kai, S; Matsuda, M; Okuda, K; Sasaki, H; Sekiguchi, H; Sumita, H; Takahashi, H; Watanabe, Y; Yokota, S, 2007) |
| "Eighty-three patients with various chronic myeloproliferative disorders [polycythemia vera (PV), essential thrombocytosis (ET), idiopathic myelofibrosis (IMF)] were analyzed for the occurrence of acute myeloid leukemia (AML) and myelodysplasia (MDS) during treatment with hydroxyurea (HU) alone or HU following treatment with busulphan (BU)." | 7.72 | Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. ( Hasselbalch, HC; Nielsen, I, 2003) |
| "In polycythemia vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%." | 7.69 | Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. ( Fisher, SG; Godwin, J; Nand, S; Stock, W, 1996) |
| "Fifty-one patients with acute nonlymphocytic leukemia (16 with end-stage disease, 17 in second or third remission or in early relapse, and 18 in first remission) were given infusions of HLA-identical sibling marrow after cytoreduction with high doses of busulfan and cyclophosphamide." | 7.66 | Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. ( Beschorner, WE; Bias, WB; Braine, HG; Brookmeyer, R; Burns, WH; Elfenbein, GJ; Kaizer, H; Santos, GW; Saral, R; Tutschka, PJ, 1983) |
| "Complete bioavailability of i." | 6.70 | Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. ( Anderlini, P; Andersson, BS; Champlin, RE; Couriel, D; de Lima, M; Gajewski, J; Madden, T; Thall, PF; Tran, HT; Wang, X, 2002) |
| "Animal models of thrombocytopenia are indispensable for evaluating the in vivo efficacy of hemostatic agents, cryopreserved platelets, and artificial platelets, but no large animal models are available." | 5.43 | A swine model of acute thrombocytopenia with prolonged bleeding time produced by busulfan. ( Abe, T; Hanazono, Y; Hishikawa, S; Kono, S; Kunita, S; Ohnuki, T, 2016) |
| "Busulfan is a commonly used chemotherapeutic agent in myeloablative conditioning regimens for allogeneic hematopoietic cell transplantation (allo-HCT)." | 5.42 | Subacute hepatic necrosis mimicking veno-occlusive disease in a patient with HFE H63D homozygosity after allogeneic hematopoietic cell transplantation with busulfan conditioning. ( Boyer, MW; Chen, S; Chen, X; Hildebrandt, GC; McDonald, GB; Osborn, JD, 2015) |
| " For graft-versus-host disease (GVHD) prophylaxis, cyclosporine and methotrexate were administered." | 5.24 | Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission. ( Baek, S; Choi, EJ; Choi, Y; Jeon, M; Jo, JC; Joo, YD; Kang, YA; Kang, YL; Kim, DY; Kim, H; Kim, SH; Ko, SH; Lee, JH; Lee, KH; Lee, YS; Lim, SN; Park, HS; Seol, M; Yun, SC, 2017) |
| "Fifty patients with high-risk hematologic malignancies, underwent an unmanipulated haploidentical bone marrow transplantation (BMT), followed by posttransplantation high-dose cyclophosphamide (PT-CY): the myeloablative (MA) conditioning consisted of thiotepa, busulfan, fludarabine (n = 35), or total body irradiation (TBI), fludarabine (n = 15)." | 5.17 | Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. ( Bacigalupo, A; Ballerini, F; Bregante, S; Di Grazia, C; Dominietto, A; Geroldi, S; Ghiso, A; Gualandi, F; Lamparelli, T; Luchetti, S; Miglino, M; Raiola, AM; Van Lint, MT; Varaldo, R, 2013) |
| "We evaluated the incidence of GVHD, risk factors and the impact of graft composition on acute GVHD (aGVHD) in 92 children who underwent BMT for thalassemia following busulfan/cyclophosphamide (BUCY)-based conditioning regimens and GVHD prophylaxis with CSA/short-MTX and methylprednisolone." | 5.16 | Higher CD3(+) and CD34(+) cell doses in the graft increase the incidence of acute GVHD in children receiving BMT for thalassemia. ( Adorno, G; Alfieri, C; Andreani, M; Daniele, N; De Angelis, G; Del Proposto, G; Gallucci, C; Gaziev, J; Isgrò, A; Lanti, A; Lucarelli, G; Marziali, M; Paciaroni, K; Roveda, A; Saltarelli, F; Simone, MD; Sodani, P; Testi, M, 2012) |
| "To reduce the incidence of graft-versus-host disease (GVHD), we added Thymoglobulin (THY) to dose-adjusted oral busulfan plus cyclophosphamide (targeted BUCY)." | 5.12 | Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. ( Anasetti, C; Appelbaum, FR; Boeckh, M; Deeg, HJ; Doney, KC; Flowers, ME; Hansen, JA; Heimfeld, S; Kiem, HP; Martin, PJ; McCune, JS; Myerson, D; Nash, RA; O'Donnell, PV; Radich, JP; Sandmaier, BM; Scott, BL; Sorror, ML; Storb, R; Storer, BE; Warren, EH; Witherspoon, RP; Woolfrey, A, 2006) |
| " From 1974 to 1986 we treated 20 symptomatic ET patients with microvascular circulation disturbances including erythromelalgia (N = 18), atypical or typical transient ischemic attacks (N = 6), or acute coronary ischemic syndrome (N = 3) with aspirin and one course of busulfan." | 5.09 | Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia. ( Michiels, JJ, 1999) |
| "We have previously demonstrated that hydroxyurea (HU) reduces the rate of vascular complications in patients with essential thrombocythaemia (ET) at high risk of thrombosis." | 5.09 | Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. ( Barbui, T; Finazzi, G; Rodeghiero, F; Ruggeri, M, 2000) |
| "In order to strengthen the anti-leukemia effect, we developed a new conditioning regimen with high dose busulfan, VP-16 and ACNU (BVA) for cytoreduction before stem cell transplantation." | 5.07 | [High-dose busulfan, VP-16 and ACNU therapy with stem cell transplantation for the treatment of children with acute leukemia]. ( Fujioka, K; Funabiki, T; Ikuta, K; Kai, S; Kajigaya, Y; Matsuyama, S; Sakai, H; Sekiguchi, H; Sumita, H; Takahashi, H, 1993) |
| " We therefore assessed 83 patients (age, 16-70 years): 68 with acute leukemia (including 34 in remission and 34 with refractory disease) and 15 patients with myelodysplastic syndrome, in HCT trials using RIC with busulfan, fludarabine, and antithymocyte globulin." | 3.77 | Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. ( Hwang, HJ; Jeon, M; Jung, AR; Kang, YA; Kim, DY; Kim, SH; Lee, JH; Lee, KH; Lee, YS; Seol, M; Shin, HJ; Yun, SC, 2011) |
| "To analyze the results of idarubicin (IDA)- versus etoposide (VP16)-intensified myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation (allo-SCT) for high-risk acute leukemia." | 3.75 | A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia. ( Chen, ZC; Li, L; Li, QB; Xia, LH; You, Y; Zou, P, 2009) |
| "We have reported a lower incidence of acute graft-versus-host disease (aGVHD) with a novel conditioning regimen using low-dose rabbit antithymocyte globulin (ATG; Thymoglobulin [TG]) with fludarabine and intravenous busulfan (FluBuTG)." | 3.74 | Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide. ( Agovi, MA; Bacigalupo, A; Bahlis, NJ; Ballen, K; Bredeson, CN; Brown, C; Chaudhry, MA; Horowitz, MM; Kurian, S; Muehlenbien, CE; Quinlan, D; Rizzo, JD; Russell, JA; Savoie, L; Stewart, DA; Zhang, MJ, 2008) |
| "We retrospectively evaluated early and long-term complications of an intensified conditioning regimen consisting of busulfan and etoposide in combination with either nimustine hydrochloride (ACNU) (BVA regimen, n = 18) or melphalan (BVL regimen, n = 34) in 52 children with acute leukemia or non-Hodgkin's lymphoma." | 3.74 | Long-term follow-up of busulfan, etoposide, and nimustine hydrochloride (ACNU) or melphalan as conditioning regimens for childhood acute leukemia and lymphoma. ( Fujioka, K; Funabiki, T; Goto, H; Goto, S; Hanzawa, N; Ikuta, K; Izaki, S; Kai, S; Matsuda, M; Okuda, K; Sasaki, H; Sekiguchi, H; Sumita, H; Takahashi, H; Watanabe, Y; Yokota, S, 2007) |
| " Conditioning regimens consisted of busulfan and cyclophosphamide, followed by cyclosporine +/- methotrexate for graft-versus-host disease (GVHD) prophylaxis." | 3.74 | Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major. ( Alimoghaddam, K; Ashouri, A; Ghaffari, H; Ghavamzadeh, A; Hadjibabaie, M; Iravani, M; Mahdavi, N; Mousavi, SA; Namdar, R; Nedaeifard, L; Shamshiri, A, 2008) |
| "Eighty-three patients with various chronic myeloproliferative disorders [polycythemia vera (PV), essential thrombocytosis (ET), idiopathic myelofibrosis (IMF)] were analyzed for the occurrence of acute myeloid leukemia (AML) and myelodysplasia (MDS) during treatment with hydroxyurea (HU) alone or HU following treatment with busulphan (BU)." | 3.72 | Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. ( Hasselbalch, HC; Nielsen, I, 2003) |
| " In this report, we analyzed the outcome of 101 high-risk patients (70 hematologic and 31 nonhematologic malignancies) who received an HLA-identical sibling allo-SCT after RIC, including fludarabine, busulfan, and antithymocyte globulin (ATG)." | 3.72 | Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. ( Bay, JO; Bilger, K; Blaise, D; Chabannon, C; Choufi, B; Coso, D; Faucher, C; Maraninchi, D; Mohty, M; Stoppa, AM; Tournilhac, O; Vey, N; Viens, P, 2003) |
| " Graft-versus-host disease (GVHD) prophylaxis was cyclosporin, prednisolone and low-dose antithymocyte globulin." | 3.70 | Acute graft-versus-host disease in thalassaemic marrow transplantation with low-dose antithymocyte globulin. ( Haghshenas, M; Khojasteh, HN; Ramzi, M; Zakerinia, M, 1999) |
| "The purpose of this study was to evaluate the influence of busulfan (BU) pharmacokinetics on survival, grades II-IV acute graft-versus-host disease (GVHD), non-relapse mortality (NRM) and relapse in a group composed of 45 children (<18 years) and seven adults with acute myeloid leukemia (AML) in first complete remission and undergoing hematopoietic stem cell transplantation (SCT)." | 3.70 | Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia. ( Baker, KS; Blazar, BR; Bostrom, B; DeFor, T; Ramsay, NK; Woods, WG, 2000) |
| "In polycythemia vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%." | 3.69 | Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. ( Fisher, SG; Godwin, J; Nand, S; Stock, W, 1996) |
| " For graft-versus-host disease prophylaxis patients received cyclosporin A (CSA) and methotrexate (MTX) (n=32), MTX alone (n=12), CSA and methylprednisone (n=5), or CSA alone (n=13)." | 3.69 | Long-term leukemia-free survival after allogeneic marrow transplantation in patients with acute myelogenous leukemia. ( Brugger, SA; Dieckmann, KU; Fischer, G; Geissler, K; Greinix, HT; Haas, O; Hinterberger, W; Hocker, P; Jager, U; Kalhs, P; Keil, F; Lechner, K; Linkesch, W; Mannhalter, C; Reiter, E; Schneider, B; Schwarzinger, I, 1996) |
| "Five of 35 AML patients undergoing autologous bone marrow transplant using busulfan, cyclophosphamide, and purged bone marrow developed evidence of acute cholecystitis." | 3.69 | Acute cholecystitis after autologous bone marrow transplantation for acute myeloid leukemia. ( Cooper, BW; Creger, RJ; Fox, RM; Jacobs, G; Kuttah, L; Lazarus, HM; Weber, F, 1995) |
| "Twenty-five patients with hematologic malignancies were treated with busulfan (16 mg/kg) and cyclophosphamide (50 mg/kg x 3 days) as conditioning for bone marrow transplantation using marrow from serologically matched, DR locus genotypically identical unrelated donors." | 3.69 | Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD. ( Brodsky, I; Bulova, S; Crilley, P; Marks, DI; Styler, MJ; Topolsky, D, 1996) |
| "The toxic effects of high-dose busulfan (16 mg/kg) and cyclophosphamide (200 mg/kg) with autologous or syngeneic bone marrow rescue were evaluated in 19 patients (11 with acute myelocytic leukemia, one with acute lymphocytic leukemia, one with acute myelofibrosis, two with chronic myelocytic leukemia, one with Hodgkin's disease, and three with non-Hodgkin's lymphoma)." | 3.67 | Preliminary results of high-dose busulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue. ( Braine, HG; Kaizer, H; Lu, C; Santos, GW; Saral, R; Tutschka, PJ, 1984) |
| "Fifty-one patients with acute nonlymphocytic leukemia (16 with end-stage disease, 17 in second or third remission or in early relapse, and 18 in first remission) were given infusions of HLA-identical sibling marrow after cytoreduction with high doses of busulfan and cyclophosphamide." | 3.66 | Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. ( Beschorner, WE; Bias, WB; Braine, HG; Brookmeyer, R; Burns, WH; Elfenbein, GJ; Kaizer, H; Santos, GW; Saral, R; Tutschka, PJ, 1983) |
| "AML patients in three CALGB hematopoietic cell transplantation studies were treated with a conditioning regimen using IV busulfan, dosed at 0." | 2.79 | Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). ( Alyea, EP; Beumer, JH; Blum, W; Christner, SM; Devine, S; Egorin, MJ; Holleran, JL; Jiang, C; Kolitz, JE; Larson, RA; Lewis, LD; Linker, C; Owzar, K; Ratain, MJ; Vij, R, 2014) |
| "The optimal pretransplant regimen for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in patients ≥ 55 years of age remains to be determined." | 2.76 | Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. ( Alatrash, G; Andersson, BS; Champlin, RE; Chiattone, A; de Lima, M; de Padua Silva, L; Giralt, SA; Hamerschlak, N; Hosing, C; Kebriaei, P; Kerbauy, F; Nieto, Y; Pelosini, M; Qazilbash, MH; Rondon, G; Saliba, RM; Wang, X; Xiao, L; Zhang, W, 2011) |
| "5-fold difference in dosing rate, (3) negligible variability in dose-to-dose pharmacokinetics and negligible interdose accumulation with once-daily administration, and (4) no change in pharmokinetic parameter(s) with concomitant use of imidazole antifungals, oral contraceptives, or phenytoin." | 2.73 | Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. ( Andersson, BS; Champlin, RE; Couriel, D; de Lima, M; Jones, RB; Madden, T; Nguyen, J; Pierre, B; Roberson, S; Shpall, EJ; Thapar, N, 2007) |
| " In summary, the combination of treosulfan and fludarabine is a safe and efficient conditioning regimen." | 2.71 | Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. ( Casper, J; Dölken, G; Freund, M; Hammer, U; Hartung, G; Kiefer, T; Kleine, HD; Knauf, W; Knopp, A; Steiner, B; Wegener, R; Wilhelm, S; Wolff, D, 2004) |
| "Complete bioavailability of i." | 2.70 | Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. ( Anderlini, P; Andersson, BS; Champlin, RE; Couriel, D; de Lima, M; Gajewski, J; Madden, T; Thall, PF; Tran, HT; Wang, X, 2002) |
| " These data suggest that dose adjustment based on first dose PK data could allow uniformity of busulfan dosing for patients receiving SCT." | 2.69 | A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation. ( Apperley, J; Craddock, C; Eades, A; Goldman, J; Hassan, M; Kanfer, E; Matthews, J; Nilsson, C; Olavarria, E; Timms, A, 2000) |
| " We investigated a 6-h and a 34-h infusion of VP-16 to compare pharmacokinetic parameters and toxicity." | 2.67 | Pharmacokinetics of high-dose VP-16: 6-hour infusion versus 34-hour infusion. ( Bewermeier, P; Hossfeld, DK; Krüger, W; Mross, K; Reifke, J; Stockschläder, M; Zander, A, 1994) |
| "Treatment with busulfan or interferon-α is usually effective in hydroxyurea failures." | 2.48 | Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. ( Tefferi, A, 2012) |
| "Total body irradiation (TBI) at a dose of 12 Gy combined with cyclophosphamide (CyTBI12Gy) is one of the standard myeloablative regimens for patients with acute myeloid leukemia (AML) treated with allogeneic hematopoietic cell transplantation (allo-HCT)." | 1.91 | Fludarabine versus cyclophospamide in combination with myeloablative total body irradiation as conditioning for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study from the Acute Leukemia Working Party ( Arat, M; Bourhis, JH; Cornelissen, JJ; Giebel, S; Grillo, G; Hilgendorf, I; Kröger, N; Labopin, M; Maertens, J; Mohty, M; Nagler, A; Poiré, X; Salmenniemi, U; Savani, B; Schroeder, T; Spyridonidis, A; Swoboda, R, 2023) |
| "In conclusion, ATG and PTCy combined with Flu-based increased intensity conditioning regimen is effective for acute leukemia in children." | 1.91 | Intensified conditioning regimen with fludarabine combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in children with high-risk acute leukemia. ( Cao, J; Chen, D; Li, S; Liu, X; Lu, Y; Pei, R; Wang, T; Xu, X; Ye, P; Zheng, ZZ, 2023) |
| "Alopecia was defined as clinically apparent decreased hair density." | 1.46 | Permanent diffuse alopecia after haematopoietic stem cell transplantation in childhood. ( Ball, LM; Bresters, D; Fiocco, M; Louwerens, M; van Doorn, R; Wanders, DCM, 2017) |
| "Animal models of thrombocytopenia are indispensable for evaluating the in vivo efficacy of hemostatic agents, cryopreserved platelets, and artificial platelets, but no large animal models are available." | 1.43 | A swine model of acute thrombocytopenia with prolonged bleeding time produced by busulfan. ( Abe, T; Hanazono, Y; Hishikawa, S; Kono, S; Kunita, S; Ohnuki, T, 2016) |
| "Animal disease models have been criticized for lack of resemblance to human illnesses, hampering transfer of knowledge from preclinical research to clinical medicine." | 1.43 | A preclinical acute GVHD mouse model based on chemotherapy conditioning and MHC-matched transplantation. ( Elezkurtaj, S; Kalupa, M; Penack, O; Riesner, K; Shi, Y, 2016) |
| "Busulfan is a commonly used chemotherapeutic agent in myeloablative conditioning regimens for allogeneic hematopoietic cell transplantation (allo-HCT)." | 1.42 | Subacute hepatic necrosis mimicking veno-occlusive disease in a patient with HFE H63D homozygosity after allogeneic hematopoietic cell transplantation with busulfan conditioning. ( Boyer, MW; Chen, S; Chen, X; Hildebrandt, GC; McDonald, GB; Osborn, JD, 2015) |
| "Cyclophosphamide combined with total body irradiation (Cy/TBI) or busulfan (BuCy) are the most widely used myeloablative conditioning regimens for allotransplants." | 1.39 | Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. ( Ahn, KW; Aljurf, M; Arora, M; Avalos, B; Bolwell, BJ; Bredeson, C; Cahn, JY; Copelan, EA; Cortes, J; Costa, LJ; de Lima, M; Gale, RP; Hale, GA; Halter, J; Hamadani, M; Hamilton, BK; Horowitz, MM; Inamoto, Y; Kalaycio, ME; Kamble, RT; Litzow, MR; Loren, AW; Marks, DI; Maziarz, RT; Olavarria, E; Roy, V; Saber, W; Sabloff, M; Savani, BN; Schouten, HC; Seftel, M; Szer, J; Ustun, C; van Besien, K; Waller, EK; Weisdorf, DJ; Wirk, B; Zhu, X, 2013) |
| "A 21-year-old woman with acute lymphoblastic leukemia underwent bone marrow transplantation (BMT)." | 1.32 | Busulfan neurotoxicity and EEG abnormalities: a case report. ( Bonifazi, F; Cirignotta, F; Guarino, M; La Morgia, C; Mondini, S, 2004) |
| "Busulfan was given as a single daily dose." | 1.31 | Growth and endocrine function in children with acute myeloid leukaemia after bone marrow transplantation using busulfan/cyclophosphamide. ( Afify, Z; Clavano-Harding, A; Cowell, CT; Shaw, PJ, 2000) |
| "To evaluate the efficacy and toxicity of two different etoposide (VP-16) dosages (30 or 45 mg/kg) in combination with busulfan/cyclophosphamide as conditioning therapy followed by stem cell transplantation in acute myeloid leukemia (AML), 90 patients with AML received either 30 mg/kg (n = 60) or 45 mg/kg (n = 30) etoposide in combination with busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg)." | 1.31 | Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia. ( Braumann, D; Colberg, H; del Valle, F; Erttmann, R; Fiedler, W; Finkenstein, F; Holstein, K; Kabisch, H; Kröger, N; Krüger, W; Kuse, R; Mayer, U; Metzner, B; Renges, H; Sonnen, R; Sonnenberg, S; Stute, N; Zabelina, T; Zander, AR, 2000) |
| " Thus, targeting avoided much of the variability in BU Css seen in other studies and appears to have allowed for an increase in oral dosing from 8 mg/kg to 10." | 1.29 | Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels. ( Appelbaum, FR; Bensinger, WI; Buckner, CD; Clift, R; Demirer, T; Fefer, A; Lambert, K; Sanders, J; Slattery, JT; Storb, R, 1996) |
| "The syndrome was characterised by sudden onset of circulatory shock and cardiac arrest." | 1.28 | Sudden cardiac tamponade after chemotherapy for marrow transplantation in thalassaemia. ( Angelucci, E; Baronciani, D; Cesaroni, P; Durazzi, SM; Galimberti, M; Giardini, C; Lucarelli, G; Mariotti, E; Muretto, P; Polchi, P, 1992) |
| "Ninety-nine patients with acute nonlymphocytic leukemia (ANLL) received HLA-identical bone marrow transplants (BMTs) from sibling donors after preparation with high doses of busulfan and cyclophosphamide." | 1.28 | Allogeneic bone marrow transplantation after high-dose busulfan and cyclophosphamide in patients with acute nonlymphocytic leukemia. ( Ambinder, RF; Beschorner, WB; Braine, HG; Burns, WH; Geller, RB; Piantadosi, S; Saral, R; Vogelsang, GB; Wingard, JR; Zahurak, M, 1989) |
| "Of 602 patients treated for non-Hodgkin's lymphomas, 9 developed overt acute nonlymphocytic leukemia or preleukemia with refractory cytopenia and cytogenetic abnormalities of the bone marrow." | 1.27 | Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. ( Ersbøll, J; Keiding, N; Larsen, MS; Larsen, SO; Nissen, NI; Pedersen-Bjergaard, J; Philip, P; Schultz, H; Sørensen, HM, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 24 (16.00) | 18.7374 |
| 1990's | 41 (27.33) | 18.2507 |
| 2000's | 48 (32.00) | 29.6817 |
| 2010's | 27 (18.00) | 24.3611 |
| 2020's | 10 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Alatrash, G | 2 |
| Saberian, C | 1 |
| Bassett, R | 1 |
| Thall, PF | 2 |
| Ledesma, C | 1 |
| Lu, Y | 2 |
| Daher, M | 1 |
| Valdez, BC | 1 |
| Kawedia, J | 1 |
| Popat, U | 1 |
| Mehta, R | 1 |
| Oran, B | 1 |
| Nieto, Y | 2 |
| Olson, A | 1 |
| Anderlini, P | 2 |
| Marin, D | 1 |
| Hosing, C | 2 |
| Alousi, AM | 1 |
| Shpall, EJ | 2 |
| Rondon, G | 2 |
| Chen, J | 1 |
| Qazilbash, M | 1 |
| Champlin, RE | 4 |
| Kebriaei, P | 2 |
| Swoboda, R | 4 |
| Labopin, M | 8 |
| Giebel, S | 5 |
| Schroeder, T | 4 |
| Kröger, N | 10 |
| Arat, M | 4 |
| Savani, B | 5 |
| Spyridonidis, A | 6 |
| Hamladji, RM | 3 |
| Potter, V | 3 |
| Berceanu, A | 3 |
| Yakoub-Agha, I | 4 |
| Rambaldi, A | 3 |
| Ozdogu, H | 3 |
| Sanz, J | 5 |
| Nagler, A | 7 |
| Mohty, M | 9 |
| Maertens, J | 2 |
| Bourhis, JH | 2 |
| Grillo, G | 1 |
| Salmenniemi, U | 1 |
| Hilgendorf, I | 2 |
| Poiré, X | 1 |
| Cornelissen, JJ | 1 |
| Bug, G | 1 |
| Niittyvuopio, R | 1 |
| Stelljes, M | 2 |
| Reinhardt, HC | 1 |
| Kaare, A | 1 |
| Bethge, W | 2 |
| Schäfer-Eckart, K | 2 |
| Verbeek, M | 1 |
| Mielke, S | 1 |
| Carlson, K | 1 |
| Bazarbachi, A | 1 |
| Savani, BN | 2 |
| Hirschbühl, K | 1 |
| Polge, E | 1 |
| Blaise, D | 3 |
| Socié, G | 2 |
| Forcade, E | 1 |
| Labussière-Wallet, H | 1 |
| Chevallier, P | 1 |
| Bonnet, S | 1 |
| Peric, Z | 1 |
| Brissot, E | 1 |
| Schmid, C | 1 |
| Ciceri, F | 2 |
| Cao, J | 1 |
| Xu, X | 2 |
| Wang, T | 1 |
| Chen, D | 1 |
| Li, S | 1 |
| Liu, X | 1 |
| Ye, P | 1 |
| Zheng, ZZ | 1 |
| Pei, R | 1 |
| Pabst, T | 1 |
| Versluis, J | 1 |
| Van Gorkom, G | 1 |
| Meijer, E | 1 |
| Gedde-Dahl, T | 1 |
| Montoro, J | 1 |
| Arcese, W | 4 |
| Pérez-Simón, JA | 1 |
| Schaap, N | 2 |
| Vrhovac, R | 1 |
| Lanza, F | 1 |
| Gorin, NC | 2 |
| Lee, SS | 1 |
| Jung, SH | 1 |
| Do, YR | 1 |
| Kim, DS | 1 |
| Lee, JH | 7 |
| Park, HS | 2 |
| Moon, JH | 1 |
| Yi, JH | 1 |
| Park, Y | 1 |
| Koh, Y | 1 |
| Yhim, HY | 1 |
| Choi, Y | 2 |
| Mun, YC | 1 |
| Lee, WS | 1 |
| Lee, S | 2 |
| Yang, DH | 1 |
| Boelens, JJ | 2 |
| Araqi Houssaini, L | 1 |
| Hali, F | 1 |
| Quessar, A | 1 |
| Marnissi, F | 1 |
| Chiheb, S | 1 |
| Bresters, D | 1 |
| Wanders, DCM | 1 |
| Louwerens, M | 1 |
| Ball, LM | 1 |
| Fiocco, M | 1 |
| van Doorn, R | 1 |
| Lee, KH | 3 |
| Kim, DY | 3 |
| Choi, EJ | 1 |
| Ko, SH | 1 |
| Seol, M | 2 |
| Lee, YS | 2 |
| Kang, YA | 2 |
| Jeon, M | 2 |
| Baek, S | 1 |
| Kang, YL | 1 |
| Kim, SH | 3 |
| Yun, SC | 2 |
| Kim, H | 1 |
| Jo, JC | 1 |
| Joo, YD | 1 |
| Lim, SN | 1 |
| Sun, L | 1 |
| Wang, N | 1 |
| Chen, Y | 1 |
| Tang, L | 1 |
| Xing, C | 1 |
| Lu, N | 1 |
| Shi, Y | 2 |
| Ma, Y | 1 |
| Lin, F | 1 |
| Yu, K | 1 |
| Feng, J | 1 |
| Kharfan-Dabaja, MA | 1 |
| Anasetti, C | 3 |
| Fernandez, HF | 1 |
| Perkins, J | 1 |
| Ochoa-Bayona, JL | 1 |
| Pidala, J | 1 |
| Perez, LE | 1 |
| Ayala, E | 1 |
| Field, T | 1 |
| Alsina, M | 1 |
| Nishihori, T | 1 |
| Locke, F | 1 |
| Pinilla-Ibarz, J | 1 |
| Tomblyn, M | 1 |
| Nishimoto, M | 2 |
| Nakamae, H | 2 |
| Watanabe, K | 1 |
| Koh, H | 2 |
| Nakane, T | 2 |
| Ohsawa, M | 1 |
| Arakawa, T | 1 |
| Hino, M | 2 |
| Copelan, EA | 2 |
| Hamilton, BK | 1 |
| Avalos, B | 1 |
| Ahn, KW | 1 |
| Bolwell, BJ | 2 |
| Zhu, X | 2 |
| Aljurf, M | 1 |
| van Besien, K | 1 |
| Bredeson, C | 2 |
| Cahn, JY | 2 |
| Costa, LJ | 1 |
| de Lima, M | 4 |
| Gale, RP | 1 |
| Hale, GA | 1 |
| Halter, J | 1 |
| Hamadani, M | 1 |
| Inamoto, Y | 1 |
| Kamble, RT | 1 |
| Litzow, MR | 1 |
| Loren, AW | 1 |
| Marks, DI | 3 |
| Olavarria, E | 2 |
| Roy, V | 1 |
| Sabloff, M | 1 |
| Seftel, M | 1 |
| Schouten, HC | 2 |
| Ustun, C | 1 |
| Waller, EK | 1 |
| Weisdorf, DJ | 1 |
| Wirk, B | 1 |
| Horowitz, MM | 2 |
| Arora, M | 1 |
| Szer, J | 1 |
| Cortes, J | 1 |
| Kalaycio, ME | 1 |
| Maziarz, RT | 1 |
| Saber, W | 1 |
| Kato, M | 1 |
| Takahashi, Y | 1 |
| Tomizawa, D | 1 |
| Okamoto, Y | 1 |
| Inagaki, J | 1 |
| Koh, K | 1 |
| Ogawa, A | 1 |
| Okada, K | 1 |
| Cho, Y | 1 |
| Takita, J | 1 |
| Goto, H | 3 |
| Sakamaki, H | 1 |
| Yabe, H | 1 |
| Kawa, K | 1 |
| Suzuki, R | 1 |
| Kudo, K | 1 |
| Kato, K | 2 |
| LeRademacher, J | 1 |
| Dipersio, JF | 1 |
| Agura, E | 1 |
| Devine, SM | 1 |
| Appelbaum, FR | 4 |
| Tomblyn, MR | 1 |
| Laport, GG | 1 |
| McCarthy, PL | 1 |
| Ho, VT | 1 |
| Cooke, KR | 1 |
| Armstrong, E | 1 |
| Smith, A | 1 |
| Rizzo, JD | 2 |
| Burkart, JM | 1 |
| Pasquini, MC | 1 |
| Abedin, S | 1 |
| Peres, E | 1 |
| Levine, JE | 2 |
| Choi, S | 1 |
| Yanik, G | 2 |
| Couriel, DR | 1 |
| Beumer, JH | 1 |
| Owzar, K | 1 |
| Lewis, LD | 1 |
| Jiang, C | 1 |
| Holleran, JL | 1 |
| Christner, SM | 1 |
| Blum, W | 2 |
| Devine, S | 1 |
| Kolitz, JE | 1 |
| Linker, C | 1 |
| Vij, R | 1 |
| Alyea, EP | 2 |
| Larson, RA | 1 |
| Ratain, MJ | 1 |
| Egorin, MJ | 1 |
| Tang, Y | 1 |
| Li, JJ | 1 |
| Chen, XC | 1 |
| Liu, ZG | 1 |
| Lu, ZP | 1 |
| Huang, XO | 1 |
| Liu, T | 1 |
| Shin, SH | 1 |
| Kim, JH | 1 |
| Jeon, YW | 1 |
| Yoon, JH | 1 |
| Yahng, SA | 1 |
| Lee, SE | 1 |
| Choi, YS | 1 |
| Kim, HJ | 2 |
| Min, CK | 1 |
| Lee, JW | 1 |
| Min, WS | 1 |
| Kim, YJ | 1 |
| Aldenhoven, M | 1 |
| Jones, SA | 1 |
| Bonney, D | 1 |
| Borrill, RE | 1 |
| Coussons, M | 1 |
| Mercer, J | 1 |
| Bierings, MB | 1 |
| Versluys, B | 1 |
| van Hasselt, PM | 1 |
| Wijburg, FA | 1 |
| van der Ploeg, AT | 1 |
| Wynn, RF | 1 |
| Piñana, JL | 1 |
| Esquirol, A | 1 |
| Martino, R | 1 |
| Picardi, A | 1 |
| Barba, P | 1 |
| Parody, R | 1 |
| Gayoso, J | 1 |
| Montesinos, P | 1 |
| Guidi, S | 1 |
| Terol, MJ | 1 |
| Moscardó, F | 1 |
| Solano, C | 1 |
| Sanz, MA | 1 |
| Sierra, J | 2 |
| Sanz, G | 1 |
| Katayama, T | 1 |
| Hayashi, Y | 1 |
| Nakashima, Y | 1 |
| Nakamae, M | 1 |
| Hirose, A | 1 |
| Chen, S | 1 |
| Osborn, JD | 1 |
| Chen, X | 1 |
| Boyer, MW | 1 |
| McDonald, GB | 1 |
| Hildebrandt, GC | 1 |
| Riesner, K | 1 |
| Kalupa, M | 1 |
| Elezkurtaj, S | 1 |
| Penack, O | 1 |
| Jaiswal, SR | 1 |
| Chakrabarti, A | 1 |
| Chatterjee, S | 1 |
| Bhargava, S | 1 |
| Ray, K | 1 |
| O'Donnell, P | 1 |
| Chakrabarti, S | 1 |
| Ji, YS | 1 |
| Lee, MS | 1 |
| Min, CW | 1 |
| Park, SK | 1 |
| Yun, J | 1 |
| Kim, KH | 1 |
| Kim, CK | 1 |
| Lee, KT | 1 |
| Won, JH | 1 |
| Hong, DS | 1 |
| Morillo-Gutierrez, B | 1 |
| Beier, R | 1 |
| Rao, K | 1 |
| Burroughs, L | 1 |
| Schulz, A | 1 |
| Ewins, AM | 1 |
| Gibson, B | 1 |
| Sedlacek, P | 1 |
| Krol, L | 1 |
| Strahm, B | 1 |
| Zaidman, I | 1 |
| Kalwak, K | 1 |
| Talano, JA | 1 |
| Woolfrey, A | 2 |
| Fraser, C | 1 |
| Meyts, I | 1 |
| Müller, I | 1 |
| Wachowiak, J | 1 |
| Bernardo, ME | 1 |
| Veys, P | 1 |
| Sykora, KW | 1 |
| Gennery, AR | 1 |
| Slatter, M | 1 |
| Abe, T | 2 |
| Kono, S | 1 |
| Ohnuki, T | 1 |
| Hishikawa, S | 1 |
| Kunita, S | 1 |
| Hanazono, Y | 1 |
| Bredeson, CN | 1 |
| Zhang, MJ | 2 |
| Agovi, MA | 1 |
| Bacigalupo, A | 2 |
| Bahlis, NJ | 1 |
| Ballen, K | 1 |
| Brown, C | 1 |
| Chaudhry, MA | 1 |
| Kurian, S | 1 |
| Quinlan, D | 1 |
| Muehlenbien, CE | 1 |
| Russell, JA | 1 |
| Savoie, L | 1 |
| Stewart, DA | 1 |
| Li, QB | 1 |
| Li, L | 1 |
| You, Y | 1 |
| Chen, ZC | 1 |
| Xia, LH | 1 |
| Zou, P | 1 |
| Yamamoto, M | 1 |
| Kuroda, J | 1 |
| Uchiyama, H | 1 |
| Kobayashi, T | 1 |
| Tsutsumi, Y | 1 |
| Ohshiro, M | 1 |
| Sasaki, N | 1 |
| Shimura, Y | 1 |
| Mizutani, S | 1 |
| Matsumoto, Y | 1 |
| Shimazaki, C | 3 |
| Horiike, S | 1 |
| Taniwaki, M | 1 |
| Gaziev, J | 1 |
| Isgrò, A | 1 |
| Marziali, M | 1 |
| Daniele, N | 1 |
| Gallucci, C | 1 |
| Sodani, P | 1 |
| Simone, MD | 1 |
| Adorno, G | 1 |
| Paciaroni, K | 1 |
| Andreani, M | 1 |
| Lanti, A | 1 |
| Del Proposto, G | 1 |
| Testi, M | 1 |
| De Angelis, G | 1 |
| Roveda, A | 1 |
| Alfieri, C | 1 |
| Saltarelli, F | 1 |
| Lucarelli, G | 3 |
| Hamerschlak, N | 1 |
| Pelosini, M | 1 |
| Wang, X | 2 |
| Xiao, L | 1 |
| Kerbauy, F | 1 |
| Chiattone, A | 1 |
| Qazilbash, MH | 1 |
| Giralt, SA | 1 |
| de Padua Silva, L | 1 |
| Zhang, W | 1 |
| Saliba, RM | 1 |
| Andersson, BS | 3 |
| Hwang, HJ | 1 |
| Jung, AR | 1 |
| Shin, HJ | 1 |
| Tefferi, A | 2 |
| Raiola, AM | 1 |
| Dominietto, A | 1 |
| Ghiso, A | 1 |
| Di Grazia, C | 1 |
| Lamparelli, T | 1 |
| Gualandi, F | 1 |
| Bregante, S | 1 |
| Van Lint, MT | 1 |
| Geroldi, S | 1 |
| Luchetti, S | 1 |
| Ballerini, F | 1 |
| Miglino, M | 1 |
| Varaldo, R | 1 |
| Shirasugi, N | 1 |
| Adams, AB | 1 |
| Durham, MM | 1 |
| Lukacher, AE | 1 |
| Xu, H | 1 |
| Rees, P | 1 |
| Cowan, SR | 1 |
| Williams, MA | 1 |
| Pearson, TC | 1 |
| Larsen, CP | 1 |
| Madden, T | 2 |
| Couriel, D | 2 |
| Tran, HT | 1 |
| Gajewski, J | 1 |
| Brauer, RB | 1 |
| Beck, T | 1 |
| Stehle, I | 1 |
| Kremer, M | 1 |
| Heidecke, CD | 1 |
| Bay, JO | 2 |
| Faucher, C | 2 |
| Choufi, B | 2 |
| Bilger, K | 2 |
| Tournilhac, O | 1 |
| Vey, N | 1 |
| Stoppa, AM | 1 |
| Coso, D | 1 |
| Chabannon, C | 2 |
| Viens, P | 2 |
| Maraninchi, D | 2 |
| Uberti, JP | 1 |
| Ayash, L | 1 |
| Reynolds, C | 1 |
| Ferrara, JL | 1 |
| Silver, SM | 1 |
| Braun, T | 1 |
| Hutchinson, R | 1 |
| Ratanatharathorn, V | 1 |
| Mineishi, S | 1 |
| Kanda, Y | 2 |
| Saito, T | 1 |
| Nakai, K | 1 |
| Makimoto, A | 1 |
| Kami, M | 2 |
| Tanosaki, R | 2 |
| Wakasugi, H | 1 |
| Tobinai, K | 1 |
| Takaue, Y | 2 |
| Ewing, JC | 1 |
| Robertson, JD | 1 |
| Kell, WJ | 1 |
| Burnett, AK | 1 |
| Ryder, D | 2 |
| Chang, J | 3 |
| Morgenstern, GR | 3 |
| Scarffe, JH | 3 |
| Chopra, R | 2 |
| Einsele, H | 1 |
| Wolff, D | 2 |
| Casper, J | 2 |
| Freund, M | 2 |
| Derigs, G | 1 |
| Wandt, H | 1 |
| Wittkowsky, G | 1 |
| Schmitz, N | 1 |
| Krüger, W | 4 |
| Zabelina, T | 4 |
| Renges, H | 3 |
| Ayuk, F | 2 |
| Krüll, A | 1 |
| Zander, A | 4 |
| Michallet, M | 1 |
| Boiron, JM | 1 |
| Gratecos, N | 1 |
| Sotto, JJ | 1 |
| François, S | 1 |
| Fleury, J | 1 |
| Gravis, G | 1 |
| Viret, F | 1 |
| Braud, AC | 1 |
| Bardou, VJ | 1 |
| Knauf, W | 1 |
| Kiefer, T | 1 |
| Steiner, B | 1 |
| Hammer, U | 1 |
| Wegener, R | 1 |
| Kleine, HD | 1 |
| Wilhelm, S | 1 |
| Knopp, A | 1 |
| Hartung, G | 1 |
| Dölken, G | 1 |
| Nielsen, I | 1 |
| Hasselbalch, HC | 1 |
| Ferry, C | 1 |
| Schetelig, J | 1 |
| Bornhäuser, M | 4 |
| Kiehl, M | 1 |
| Schwerdtfeger, R | 1 |
| Runde, V | 1 |
| Held, TK | 1 |
| Thiede, C | 3 |
| Fauser, AA | 1 |
| Beelen, D | 1 |
| Ehninger, G | 4 |
| Siegert, W | 1 |
| La Morgia, C | 1 |
| Mondini, S | 1 |
| Guarino, M | 1 |
| Bonifazi, F | 1 |
| Cirignotta, F | 1 |
| Ferrara, F | 3 |
| Palmieri, S | 3 |
| Annunziata, M | 2 |
| Viola, A | 3 |
| Pocali, B | 2 |
| Califano, C | 1 |
| D'Arco, AM | 1 |
| Mele, G | 3 |
| Massenkeil, G | 1 |
| Nagy, M | 1 |
| Le Coutre, P | 1 |
| Heine, F | 1 |
| Rosen, O | 1 |
| Dörken, B | 1 |
| Arnold, R | 1 |
| De Simone, M | 2 |
| Sagristani, M | 1 |
| Fasanaro, A | 1 |
| Farag, SS | 1 |
| Elder, PJ | 1 |
| Kalaycio, M | 1 |
| Lin, T | 1 |
| Pohlman, B | 1 |
| Penza, S | 1 |
| Marcucci, G | 1 |
| Sobecks, R | 1 |
| Avalos, BR | 2 |
| Byrd, JC | 1 |
| Copelan, E | 1 |
| Lu, DP | 1 |
| Dong, L | 1 |
| Wu, T | 1 |
| Huang, XJ | 1 |
| Han, W | 1 |
| Chen, H | 1 |
| Liu, DH | 1 |
| Gao, ZY | 1 |
| Chen, YH | 1 |
| Xu, LP | 1 |
| Zhang, YC | 1 |
| Ren, HY | 1 |
| Li, D | 1 |
| Liu, KY | 1 |
| Shimoni, A | 1 |
| Schieder, H | 1 |
| Panse, J | 1 |
| Wolschke, C | 1 |
| Dahlke, J | 1 |
| Atanackovic, D | 1 |
| Shaiegan, M | 1 |
| Iravani, M | 2 |
| Babaee, GR | 1 |
| Ghavamzadeh, A | 2 |
| Deeg, HJ | 3 |
| Storer, BE | 1 |
| Boeckh, M | 1 |
| Martin, PJ | 1 |
| McCune, JS | 1 |
| Myerson, D | 1 |
| Heimfeld, S | 1 |
| Flowers, ME | 1 |
| Doney, KC | 2 |
| Hansen, JA | 1 |
| Kiem, HP | 1 |
| Nash, RA | 1 |
| O'Donnell, PV | 1 |
| Radich, JP | 1 |
| Sandmaier, BM | 1 |
| Scott, BL | 1 |
| Sorror, ML | 1 |
| Warren, EH | 1 |
| Witherspoon, RP | 1 |
| Storb, R | 3 |
| Kim, HT | 1 |
| Ho, V | 1 |
| Cutler, C | 1 |
| DeAngelo, DJ | 1 |
| Stone, R | 1 |
| Ritz, J | 1 |
| Antin, JH | 1 |
| Soiffer, RJ | 1 |
| Chantry, AD | 1 |
| Snowden, JA | 1 |
| Craddock, C | 2 |
| Peggs, K | 1 |
| Roddie, C | 1 |
| Craig, JI | 1 |
| Orchard, K | 1 |
| Towlson, KE | 1 |
| Pearce, RM | 1 |
| Thapar, N | 1 |
| Nguyen, J | 1 |
| Roberson, S | 1 |
| Pierre, B | 1 |
| Jones, RB | 1 |
| Demidova, IA | 1 |
| Parovichnikova, EN | 1 |
| Kut'ina, RM | 1 |
| Poreshina, LP | 1 |
| Shpakova, AP | 1 |
| Ol'shanskaia, IuV | 1 |
| Misiurin, AV | 1 |
| Savchenko, VG | 1 |
| Izaki, S | 1 |
| Okuda, K | 1 |
| Matsuda, M | 1 |
| Watanabe, Y | 1 |
| Fujioka, K | 2 |
| Hanzawa, N | 1 |
| Sumita, H | 2 |
| Takahashi, H | 2 |
| Goto, S | 1 |
| Kai, S | 2 |
| Sekiguchi, H | 2 |
| Funabiki, T | 2 |
| Sasaki, H | 1 |
| Ikuta, K | 2 |
| Yokota, S | 1 |
| Ashouri, A | 1 |
| Mousavi, SA | 1 |
| Mahdavi, N | 1 |
| Shamshiri, A | 1 |
| Hadjibabaie, M | 1 |
| Namdar, R | 1 |
| Nedaeifard, L | 1 |
| Ghaffari, H | 1 |
| Alimoghaddam, K | 1 |
| Murashige, N | 1 |
| Mori, S | 1 |
| Katayama, Y | 1 |
| Kobayashi, K | 1 |
| Onishi, Y | 1 |
| Hori, A | 1 |
| Kishi, Y | 1 |
| Hamaki, T | 1 |
| Tajima, K | 1 |
| Santos, GW | 3 |
| Tutschka, PJ | 2 |
| Brookmeyer, R | 1 |
| Saral, R | 4 |
| Beschorner, WE | 2 |
| Bias, WB | 1 |
| Braine, HG | 4 |
| Burns, WH | 3 |
| Elfenbein, GJ | 1 |
| Kaizer, H | 3 |
| Zwaan, FE | 1 |
| Jansen, J | 1 |
| Lu, C | 1 |
| Nagao, T | 1 |
| Yamauchi, K | 1 |
| Komatsuda, M | 1 |
| Saranath, D | 1 |
| Advani, S | 1 |
| Gangal, S | 1 |
| Thomas, ED | 2 |
| Woodruff, RK | 1 |
| Rosenthal, MA | 1 |
| Grigg, AP | 1 |
| Sheridan, WP | 1 |
| Clift, RA | 1 |
| Buckner, CD | 4 |
| Bryant, E | 1 |
| Bensinger, WI | 3 |
| Bowden, R | 1 |
| Fisher, LD | 1 |
| Stemmelin, GR | 1 |
| Pest, P | 1 |
| Peters, RA | 1 |
| Ceresetto, JM | 1 |
| Shanley, CM | 1 |
| Bullorsky, EO | 1 |
| Kuttah, L | 1 |
| Weber, F | 1 |
| Creger, RJ | 1 |
| Fox, RM | 1 |
| Cooper, BW | 1 |
| Jacobs, G | 1 |
| Lazarus, HM | 1 |
| Klingemann, HG | 2 |
| Shepherd, JD | 2 |
| Reece, DE | 2 |
| Barnett, MJ | 2 |
| Nantel, SH | 2 |
| Sutherland, HJ | 1 |
| Spinelli, JJ | 1 |
| Phillips, GL | 2 |
| Mitchell, PL | 1 |
| Shepherd, VB | 1 |
| Proctor, HM | 1 |
| Dainton, M | 1 |
| Cabral, SD | 1 |
| Pinkerton, CR | 1 |
| Ashihara, E | 1 |
| Yamagata, N | 1 |
| Hirata, T | 1 |
| Okawa, K | 1 |
| Oku, N | 1 |
| Inaba, T | 1 |
| Fujita, N | 1 |
| Nakagawa, M | 1 |
| Mross, K | 1 |
| Bewermeier, P | 1 |
| Reifke, J | 1 |
| Stockschläder, M | 1 |
| Hossfeld, DK | 1 |
| Brenner, M | 1 |
| Krance, R | 1 |
| Heslop, HE | 1 |
| Santana, V | 1 |
| Ihle, J | 1 |
| Ribeiro, R | 1 |
| Roberts, WM | 1 |
| Mahmoud, H | 1 |
| Boyett, J | 1 |
| Moen, RC | 1 |
| Kajigaya, Y | 1 |
| Sakai, H | 1 |
| Matsuyama, S | 1 |
| Xun, CQ | 1 |
| Thompson, JS | 1 |
| Jennings, CD | 1 |
| Brown, SA | 1 |
| Widmer, MB | 1 |
| Inoue, T | 1 |
| Ikeda, H | 1 |
| Yamazaki, H | 1 |
| Tang, JT | 1 |
| Song, C | 1 |
| Teshima, T | 2 |
| Murayama, S | 1 |
| Ohtani, M | 1 |
| Shibata, H | 1 |
| Masaoka, T | 1 |
| Grande, M | 1 |
| Greinix, HT | 1 |
| Keil, F | 1 |
| Brugger, SA | 1 |
| Reiter, E | 1 |
| Linkesch, W | 1 |
| Lechner, K | 1 |
| Schneider, B | 1 |
| Dieckmann, KU | 1 |
| Fischer, G | 1 |
| Schwarzinger, I | 1 |
| Haas, O | 1 |
| Hinterberger, W | 1 |
| Mannhalter, C | 1 |
| Geissler, K | 1 |
| Hocker, P | 1 |
| Jager, U | 1 |
| Kalhs, P | 1 |
| Nand, S | 1 |
| Stock, W | 1 |
| Godwin, J | 1 |
| Fisher, SG | 1 |
| Ringdén, O | 1 |
| Tura, S | 2 |
| Iriondo, A | 1 |
| Zittoun, R | 1 |
| Klein, JL | 1 |
| Belt, P | 1 |
| Taylor, CA | 1 |
| Ezzone, SA | 1 |
| Scholl, MD | 1 |
| Fisher, J | 1 |
| Young, D | 1 |
| Demirer, T | 2 |
| Sanders, J | 2 |
| Lambert, K | 1 |
| Clift, R | 2 |
| Fefer, A | 2 |
| Slattery, JT | 1 |
| Topolsky, D | 2 |
| Crilley, P | 2 |
| Styler, MJ | 1 |
| Bulova, S | 1 |
| Brodsky, I | 2 |
| Petersen, FB | 1 |
| Rowley, S | 1 |
| Chauncey, T | 1 |
| Lilleby, K | 1 |
| Erer, B | 1 |
| Polchi, P | 2 |
| Angelucci, E | 2 |
| Baronciani, D | 2 |
| Galimberti, M | 2 |
| Giardini, C | 2 |
| Gaziev, D | 1 |
| Maiello, A | 1 |
| Dusenbery, KE | 1 |
| Steinbuch, M | 1 |
| McGlave, PB | 1 |
| Ramsay, NK | 2 |
| Blazar, BR | 2 |
| Neglia, JP | 1 |
| Litz, C | 1 |
| Kersey, JH | 1 |
| Woods, WG | 2 |
| Sánchez Fayos, J | 1 |
| Román Barbero, A | 1 |
| Nevado Reviriego, I | 1 |
| Gondo, H | 1 |
| Harada, M | 1 |
| Miyamoto, T | 1 |
| Takenaka, K | 1 |
| Tanimoto, K | 1 |
| Mizuno, S | 1 |
| Fujisaki, T | 1 |
| Nagafuji, K | 1 |
| Hayashi, S | 1 |
| Eto, T | 1 |
| Taniguchi, S | 1 |
| Akashi, K | 1 |
| Harada, N | 1 |
| Yamasaki, K | 1 |
| Shibuya, T | 1 |
| Matsuishi, E | 1 |
| Ohno, Y | 1 |
| Makino, S | 1 |
| Takamatsu, Y | 1 |
| Murakawa, M | 1 |
| Hirota, Y | 1 |
| Okamura, T | 1 |
| Kinukawa, N | 1 |
| Niho, Y | 1 |
| Jowitt, SN | 1 |
| Howe, T | 1 |
| Ryder, WD | 1 |
| Testa, NG | 1 |
| Sonneveld, P | 1 |
| Laméris, JS | 1 |
| Cornelissen, J | 1 |
| Ogilvie, A | 1 |
| Löwenberg, B | 2 |
| Jerjis, S | 1 |
| Roovers, E | 1 |
| Muus, P | 1 |
| de Witte, T | 1 |
| Linker, CA | 2 |
| Ries, CA | 2 |
| Damon, LE | 2 |
| Rugo, HS | 2 |
| Wolf, JL | 1 |
| Manley, R | 1 |
| Cochrane, J | 1 |
| McDonald, M | 1 |
| Rigby, S | 1 |
| Moore, A | 1 |
| Kirk, A | 1 |
| Clarke, S | 1 |
| Crossen, PE | 1 |
| Morris, CM | 1 |
| Patton, WN | 1 |
| Zander, AR | 2 |
| Berger, C | 1 |
| Stockshläder, M | 1 |
| Horstmann, M | 1 |
| Grimm, J | 1 |
| Zeller, W | 1 |
| Kabisch, H | 2 |
| Erttmann, R | 2 |
| Schönrock, P | 1 |
| Kuse, R | 2 |
| Braumann, D | 2 |
| Illiger, HJ | 1 |
| Fiedler, W | 2 |
| de Witt, M | 1 |
| Hossfeld, KD | 1 |
| Weh, HJ | 1 |
| Lemoli, RM | 1 |
| Visani, G | 1 |
| Leopardi, G | 1 |
| Motta, MR | 1 |
| Rizzi, S | 1 |
| Testoni, N | 1 |
| Curti, A | 1 |
| Vellenga, E | 1 |
| van Putten, WL | 1 |
| Boogaerts, MA | 1 |
| Daenen, SM | 1 |
| Verhoef, GE | 1 |
| Hagenbeek, A | 1 |
| Jonkhoff, AR | 1 |
| Huijgens, PC | 1 |
| Verdonck, LF | 1 |
| van der Lelie, J | 1 |
| Gmür, J | 1 |
| Wijermans, P | 1 |
| Gratwohl, A | 1 |
| Hess, U | 1 |
| Fey, MF | 1 |
| Hatta, Y | 1 |
| Itoh, T | 1 |
| Baba, M | 1 |
| Shimojima, H | 1 |
| Miyajima, T | 1 |
| Izumi, T | 1 |
| Horikoshi, A | 1 |
| Takeuchi, J | 1 |
| Sawada, U | 1 |
| Horie, T | 1 |
| Sayre, P | 1 |
| Navarro, W | 1 |
| Rubin, A | 1 |
| Case, D | 1 |
| Zamkoff, K | 1 |
| Wolfe, JL | 1 |
| Michiels, JJ | 1 |
| Randi, ML | 1 |
| Rossi, C | 1 |
| Fabris, F | 1 |
| Girolami, A | 1 |
| Khojasteh, HN | 1 |
| Zakerinia, M | 1 |
| Ramzi, M | 1 |
| Haghshenas, M | 1 |
| Ball, ED | 1 |
| Wilson, J | 1 |
| Phelps, V | 1 |
| Neudorf, S | 1 |
| Afify, Z | 1 |
| Shaw, PJ | 1 |
| Clavano-Harding, A | 1 |
| Cowell, CT | 1 |
| Finazzi, G | 1 |
| Ruggeri, M | 1 |
| Rodeghiero, F | 1 |
| Barbui, T | 1 |
| Baker, KS | 1 |
| Bostrom, B | 1 |
| DeFor, T | 1 |
| Sonnenberg, S | 1 |
| Stute, N | 1 |
| Finkenstein, F | 1 |
| Mayer, U | 1 |
| Holstein, K | 1 |
| Colberg, H | 1 |
| Sonnen, R | 1 |
| Metzner, B | 1 |
| del Valle, F | 1 |
| Hassan, M | 1 |
| Eades, A | 1 |
| Nilsson, C | 1 |
| Timms, A | 1 |
| Matthews, J | 1 |
| Kanfer, E | 1 |
| Apperley, J | 1 |
| Goldman, J | 1 |
| Platzbecker, U | 2 |
| Freiberg-Richter, J | 2 |
| Röllig, C | 2 |
| Helwig, A | 2 |
| Schäkel, U | 1 |
| Mohr, B | 1 |
| Schaich, M | 1 |
| Jenke, A | 2 |
| Plettig, R | 1 |
| Geissler, G | 1 |
| Lutterbeck, K | 1 |
| Oelschlagel, U | 1 |
| Schuler, US | 1 |
| Renner, UD | 1 |
| Kroschinsky, F | 1 |
| Johne, C | 1 |
| Naumann, R | 1 |
| Mengarelli, A | 1 |
| Iori, A | 1 |
| Guglielmi, C | 1 |
| Romano, A | 1 |
| Cerretti, R | 1 |
| Torromeo, C | 1 |
| Micozzi, A | 1 |
| Fenu, S | 1 |
| Laurenti, L | 1 |
| Donato, V | 1 |
| De Felice, L | 1 |
| Zhu, K | 1 |
| Xu, Y | 1 |
| Wu, D | 1 |
| Huang, L | 1 |
| Schiavone, EM | 1 |
| Copia, C | 1 |
| Pollio, F | 1 |
| Russo, C | 1 |
| Bordigoni, P | 1 |
| Turello, R | 1 |
| Clement, L | 1 |
| Lascombes, P | 1 |
| Leheup, B | 1 |
| Galloy, MA | 1 |
| Plenat, F | 1 |
| Ayas, M | 1 |
| Belgaumi, A | 1 |
| Al-Mahr, M | 1 |
| Al-Jefri, A | 1 |
| Solh, H | 1 |
| Leung, W | 1 |
| Anger, G | 1 |
| Senf, L | 1 |
| Schmidt, U | 1 |
| Mattheus, A | 1 |
| MacDougall, BK | 1 |
| Weinerman, BH | 1 |
| Kemel, S | 1 |
| Stott, H | 1 |
| Fox, W | 1 |
| Girling, DJ | 1 |
| Stephens, RJ | 1 |
| Galton, DA | 1 |
| Mariotti, E | 1 |
| Cesaroni, P | 1 |
| Durazzi, SM | 1 |
| Muretto, P | 1 |
| Nevill, TJ | 1 |
| Bianco, J | 1 |
| Petersen, F | 1 |
| Appelbaum, F | 1 |
| Meloni, G | 1 |
| Raucci, U | 1 |
| Pinto, RM | 1 |
| Spalice, A | 1 |
| Vignetti, M | 1 |
| Iannetti, P | 1 |
| Goldstone, AH | 1 |
| McMillan, AK | 1 |
| Powles, R | 1 |
| Smith, AG | 1 |
| Prentice, HG | 1 |
| Reid, C | 1 |
| Marcus, R | 1 |
| Bell, A | 1 |
| Milligan, D | 1 |
| Ranson, MR | 1 |
| Anderson, H | 1 |
| Deakin, DP | 1 |
| Oppenheim, B | 1 |
| Heron, D | 1 |
| Geller, RB | 1 |
| Piantadosi, S | 1 |
| Zahurak, M | 1 |
| Vogelsang, GB | 1 |
| Wingard, JR | 1 |
| Ambinder, RF | 2 |
| Beschorner, WB | 1 |
| Yeager, AM | 1 |
| Colvin, OM | 1 |
| Stuart, RK | 1 |
| Burke, PJ | 1 |
| Pedersen-Bjergaard, J | 1 |
| Ersbøll, J | 1 |
| Sørensen, HM | 1 |
| Keiding, N | 1 |
| Larsen, SO | 1 |
| Philip, P | 1 |
| Larsen, MS | 1 |
| Schultz, H | 1 |
| Nissen, NI | 1 |
| Möller, H | 1 |
| Waldenström, J | 1 |
| Cardamone, JM | 1 |
| Edson, JR | 1 |
| McArthur, JR | 1 |
| Jacob, HS | 1 |
| Dyk, T | 1 |
| Piotrowski, M | 1 |
| Kostecka, W | 1 |
| Estevez, JM | 1 |
| Urueta, EE | 1 |
| Moran, TJ | 1 |
| Wasserman, LR | 1 |
| Hoshino, T | 1 |
| Kawasaki, S | 1 |
| Okada, H | 1 |
| Yamamoto, T | 1 |
| Kimura, K | 1 |
| Gibson, OM | 1 |
| Burgess, MA | 1 |
| Stanley, LG | 1 |
| Koza, I | 1 |
| Cerný, V | 1 |
| Bohunický, L | 1 |
| Hal'ko, J | 1 |
| Ujházy, V | 1 |
| Petrek, C | 1 |
| Krizan, Z | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Trial of Haploidentical Natural Killer (NK) Cells in Combination With Pemetrexed in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)[NCT03366064] | Phase 1 | 5 participants (Actual) | Interventional | 2017-11-09 | Completed | ||
| Allogeneic HCT From Donor-sources of Matched-sibling, Matched-unrelated, or Haploidentical-family Donors Using Uniform Conditioning Regimen of Busulfan, Fludarabine, and Antithymocyte Globulin for AML in Remission - an Observational Study[NCT03337568] | 110 participants (Anticipated) | Observational | 2017-04-01 | Recruiting | |||
| Trial Of Double Umbilical Cord Blood Transplantation[NCT00763490] | Phase 2 | 20 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| The Use of Granulocyte Transfusions After Umbilical Cord Blood Transplant for Leukaemia: A Prospective, Non-randomised, Single-centre Study to Evaluate Safety and Immune Reconstitution[NCT05425043] | 20 participants (Anticipated) | Interventional | 2021-09-14 | Recruiting | |||
| Phase I/II Study Evaluating Safety and Efficacy of Autologous Hematopoietic Stem and Progenitor Cells Genetically Modified With IDUA Lentiviral Vector Encoding for the Human α-L-iduronidase Gene for the Treatment of Patients Affected by Mucopolysaccharido[NCT03488394] | Phase 1/Phase 2 | 8 participants (Actual) | Interventional | 2018-05-11 | Active, not recruiting | ||
| PRO#1278: A Phase III Study of Fludarabine and Busulfan Versus Fludarabine, Busulfan and Low Dose Total Body Irradiation in Patients Receiving an Allogeneic Hematopoietic Stem Cell Transplant[NCT01366612] | Phase 3 | 53 participants (Actual) | Interventional | 2010-06-16 | Terminated (stopped due to Lack of Accrual) | ||
| Intensive Conditioning Regimen With Thiotepa Combined With Busulfan, Fludarabine and Cytarabine for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Myeloid Malignancies With Extramedullary Involvement[NCT06111612] | 50 participants (Anticipated) | Observational | 2024-01-01 | Not yet recruiting | |||
| NON-T-CELL DEPLETED HLA-HAPLOIDENTICAL FAMILIAL DONOR HEMATOPOIETIC CELL TRANSPLANTATION AFTER REDUCED INTENSITY CONDITIONING[NCT00521430] | 30 participants (Anticipated) | Interventional | 2004-04-30 | Completed | |||
| HLA-HAPLOIDENTICAL FAMILIAL DONOR HEMATOPOIETIC CELL TRANSPLANTATION AFTER REDUCED INTENSITY CONDITIONING OF BUSULFAN, FLUDARABINE, AND ANTI-THYMOCYTE GLOBULIN FOR ADULT PATIENTS WITH HEMATOLOGIC MALIGNANCIES AND MYELODYSPLASTIC SYNDROME - A PHASE 2 STUDY[NCT00732316] | Phase 2 | 54 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| A Prospective Study Evaluating the Efficacy of the Allogeneic Hematopoietic Cell Transplantation With Antithymocyte Globulin (ATG)-Based Conditioning of Adult Acute Lymphoblastic Leukemia in First / Second Complete Hematologic Remission[NCT02428517] | 20 participants (Actual) | Observational | 2015-04-30 | Terminated (stopped due to The PI resigned the institute, and the rest investigators at the institute decided to terminate the study.) | |||
| HLA-Haploidentical Hematopoietic Cell Transplantation and Subsequent Donor Natural Killer Cell Infusion in Refractory Acute Leukemia - A Phase 1-2a STUDY[NCT01795378] | Phase 1/Phase 2 | 56 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| Bone Marrow Transplantation HLA Haploidentical After a Reduced Intensity Conditioning and Prevention of GvHD Based on Post-transplant Cyclophosphamide Administration in Patients With Severe Sickle Cell Disease[NCT03240731] | Phase 2 | 18 participants (Anticipated) | Interventional | 2017-08-10 | Active, not recruiting | ||
| Allogeneic Stem Cell Transplantation With Alternative Donor in Treatment of Hematologic Malignancy[NCT02487069] | 876 participants (Actual) | Interventional | 2015-06-30 | Completed | |||
| Phase II Trial of Fludarabine Combined With Intravenous Treosulfan and Allogeneic Hematopoietic Stem-cell Transplantation in Patients With Chemo-refractory or Previously Untreated Acute Myeloid Leukemia and Myelodysplastic Syndrome.[NCT00491634] | Phase 2 | 24 participants (Anticipated) | Interventional | 2007-06-30 | Completed | ||
| Single Arm Phase II Study of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia (ALL) in Older Patients Using Fludarabine and Total Body Irradiation (FluTBI) Regimen[NCT01991457] | Phase 2 | 19 participants (Actual) | Interventional | 2013-08-27 | Completed | ||
| A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793] | Phase 2 | 11 participants (Actual) | Interventional | 2010-10-14 | Terminated (stopped due to The clinical trial was terminated due to poor enrollment) | ||
| Phase II Study of Early Allogeneic Blood Stem Cell Transplantation During Induction-chemotherapy Induced Aplasia in High-risk Acute Myeloid Leukemia[NCT00188136] | Phase 2 | 32 participants (Actual) | Interventional | 2002-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
One-year survival rate after transplant (NCT00763490)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| Double Cord Blood Tranplant | 40 |
Event Free Survival (EFS) was determined. Patients were followed up to 5 years (median time of 2.35 years). (NCT00763490)
Timeframe: 5 Years
| Intervention | percentage of patients (Number) |
|---|---|
| Double Cord Blood Tranplant | 35 |
The failure to achieve a neutrophil count > 500/uL or a platelet count >30.0 x 10e9 /L within 35 days of the stem cell infusion will be defined as primary engraftment failure. (NCT00763490)
Timeframe: Day 35
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Cumulative incidence of platlet engraftment | Cumulative incidence of neutrophil engraftment | |
| Double Cord Blood Tranplant | 73 | 89 |
"The percentage of patients with acute GVHD (Grade II-IV) was determined at 100 days. Patients were followed up to 5 years and the percentage of patients that developed chronic GVHD at the end of the study was tabulated.~Acute GVHD is staged and graded (grade 0-IV, where grade 0 is no involvement and involvement increases by grade) by the number and extent of organ involvement. Patients can have involvement of three organs: skin (rash/dermatitis), liver (hepatitis/jaundice), and gastrointestinal tract (abdominal pain/diarrhea)." (NCT00763490)
Timeframe: Up to 5 years
| Intervention | percentage of patients (Number) | |
|---|---|---|
| Acute GVHD (Grades II-IV) | Chronic GVHD | |
| Double Cord Blood Tranplant | 40 | 35 |
(NCT01366612)
Timeframe: 1 year
| Intervention | Percent (Number) |
|---|---|
| Group 1 | 38.9 |
| Group 2 | 18.8 |
Percentage of patients without relapse of disease at 2 years (NCT01991457)
Timeframe: 2 years post-transplant
| Intervention | percentage of participants (Number) |
|---|---|
| Treatment | 63.2 |
Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year
| Intervention | dose in mg/m^2 (Number) |
|---|---|
| DRBEAT Regimen | 773.25 |
"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years
| Intervention | Days (Median) | |
|---|---|---|
| Progression Free Survival | Overall Survival | |
| DRBEAT Regimen | 132 | 564 |
10 reviews available for busulfan and Acute Disease
| Article | Year |
|---|---|
Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Topics: Acute Disease; Age Factors; Alkylating Agents; Anticoagulants; Aspirin; Busulfan; Disease Management | 2012 |
Busulfan-cyclophosphamide versus total body irradiation-cyclophosphamide as preparative regimen before allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia: what have we learned?
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; | 2003 |
Bone marrow transplantation in acute nonlymphoblastic leukemia.
Topics: Acute Disease; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; C | 1984 |
Destruction of the intestinal mucosa after bone marrow transplantation and graft-versus-host disease.
Topics: Acute Disease; Bone Marrow Transplantation; Busulfan; Chronic Disease; Combined Modality Therapy; Cy | 1984 |
Chronic myeloid leukaemia.
Topics: Acute Disease; Adult; Bone Marrow Transplantation; Busulfan; Cell Transformation, Neoplastic; Child, | 1981 |
Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia.
Topics: Acute Disease; Adult; Bone Marrow Transplantation; Busulfan; Cause of Death; Child; Combined Modalit | 1994 |
Regimen-related acute toxicities: pathophysiology, risk factors, clinical evaluation and preventive strategies.
Topics: Acute Disease; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Tr | 1994 |
[Efficacious treatment of a fatal blood disease: polycythemia vera].
Topics: Acute Disease; Alkylating Agents; Busulfan; Chlorambucil; Humans; Hydroxyurea; Leukemia, Myeloid; Le | 1997 |
[Myelocytic leukemia: cytogenetic consideration].
Topics: Acute Disease; Aneuploidy; Bone Marrow; Bone Marrow Cells; Busulfan; Cell Transformation, Neoplastic | 1975 |
The management of polycythaemia vera.
Topics: Acute Disease; Alkylating Agents; Bloodletting; Bone Marrow Diseases; Busulfan; Humans; Leukemia; Ph | 1971 |
42 trials available for busulfan and Acute Disease
| Article | Year |
|---|---|
Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study Outcomes.
Topics: Acute Disease; Busulfan; Clofarabine; Drug Therapy, Combination; Graft vs Host Disease; Hematopoieti | 2022 |
Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Cyclophosph | 2017 |
Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Cyclophosph | 2017 |
Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Cyclophosph | 2017 |
Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Cyclophosph | 2017 |
Unrelated Donor Peripheral Blood Stem Cell Transplantation for Patients with β-Thalassemia Major Based on a Novel Conditioning Regimen.
Topics: Acute Disease; Adult; Allografts; Antilymphocyte Serum; beta-Thalassemia; Busulfan; Child; Child, Pr | 2019 |
Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Busulfan; CD4 Lymphocyte Count; CD4-Positive T-Ly | 2013 |
Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation.
Topics: Acute Disease; Administration, Intravenous; Adolescent; Adult; Antineoplastic Combined Chemotherapy | 2013 |
Double umbilical cord blood transplantation after novel myeloablative conditioning using a regimen of fludarabine, busulfan, and total lymphoid irradiation.
Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Child; Child, Preschool; Chronic Disease; Cord Blo | 2014 |
Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103).
Topics: Acute Disease; Age Factors; Aged; Area Under Curve; Busulfan; Female; Hematopoietic Stem Cell Transp | 2014 |
Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease.
Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Cord Blood Stem Cell Transpla | 2016 |
Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Children with Advanced Acute Leukemia with Fludarabine-, Busulfan-, and Melphalan-Based Conditioning.
Topics: Acute Disease; Adolescent; Adult; Allografts; Busulfan; Child; Child, Preschool; Chronic Disease; Cy | 2016 |
Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience.
Topics: Acute Disease; Adolescent; Adult; Allografts; Blood Platelets; Busulfan; Child; Child, Preschool; Di | 2016 |
Higher CD3(+) and CD34(+) cell doses in the graft increase the incidence of acute GVHD in children receiving BMT for thalassemia.
Topics: Acute Disease; Adolescent; Anti-Inflammatory Agents; Antigens, CD34; Bone Marrow Transplantation; Bu | 2012 |
Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival | 2011 |
Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan | 2013 |
Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; | 2002 |
Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Graft vs Host | 2003 |
Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM).
Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Cyclophosphamide; Disease-Fre | 2003 |
Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation.
Topics: Acute Disease; Adult; Aged; Alkylating Agents; Busulfan; Chronic Disease; Family; Female; Histocompa | 2004 |
Continuous infusion idarubicin and oral busulfan as conditioning for patients with acute myeloid leukemia aged over 60 years undergoing autologous stem cell transplantation.
Topics: Acute Disease; Administration, Oral; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkyl | 2004 |
High-dose idarubicin and busulphan as conditioning to autologous stem cell transplantation in adult patients with acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Busulfan; Drug Administration Schedule; Female; Follow-Up Studies; | 2005 |
High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of | 2005 |
Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bu | 2006 |
Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Cause of Death; Child; Chron | 2006 |
Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Area Under Curve; Busulfan; Drug Admin | 2007 |
High dose busulphan/cyclophosphamide for autologous bone marrow transplantation is associated with minimal non-hemopoietic toxicity.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protoco | 1994 |
Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia.
Topics: Acute Disease; Adult; Bone Marrow Transplantation; Busulfan; Cause of Death; Child; Combined Modalit | 1994 |
Pharmacokinetics of high-dose VP-16: 6-hour infusion versus 34-hour infusion.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan | 1994 |
[High-dose busulfan, VP-16 and ACNU therapy with stem cell transplantation for the treatment of children with acute leukemia].
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantati | 1993 |
Bone marrow engraftment following unrelated donor transplantation utilizing busulfan and cyclophosphamide preparatory chemotherapy.
Topics: Acute Disease; Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Ch | 1996 |
Autologous bone marrow transplantation in acute myeloid leukemia: the University of Minnesota experience.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Bu | 1996 |
Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Co | 1997 |
Idarubicin to intensify the conditioning regimens of autologous bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; B | 1998 |
High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transp | 1997 |
Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia?
Topics: Acute Disease; Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Agents, Alkylating; Bone Marr | 1999 |
Autologous stem cell transplantation for acute myeloid leukemia in first remission.
Topics: Acute Disease; Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protoco | 2000 |
Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Busulfan; Coronary Disease; Dise | 1999 |
Autologous bone marrow transplantation for acute myeloid leukemia in remission or first relapse using monoclonal antibody-purged marrow: results of phase II studies with long-term follow-up.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antibodies, Monoclonal; Antigens, CD34; Bone Ma | 2000 |
Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Busul | 2000 |
A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation.
Topics: Acute Disease; Adult; Busulfan; Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Cyc | 2000 |
Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy P | 2001 |
High-dose idarubicin and busulphan as conditioning for autologous stem cell transplantation in acute myeloid leukemia: a feasibility study.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Feasibil | 2001 |
Acute leukaemia after busulphan.
Topics: Acute Disease; Bronchial Neoplasms; Busulfan; Cyclophosphamide; Dose-Response Relationship, Drug; Hu | 1977 |
Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide.
Topics: Acute Disease; Adolescent; Adult; Bone Marrow; Bone Marrow Transplantation; Busulfan; Child; Child, | 1986 |
99 other studies available for busulfan and Acute Disease
| Article | Year |
|---|---|
Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Par
Topics: Acute Disease; Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Huma | 2023 |
Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Par
Topics: Acute Disease; Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Huma | 2023 |
Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Par
Topics: Acute Disease; Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Huma | 2023 |
Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Par
Topics: Acute Disease; Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Huma | 2023 |
Fludarabine versus cyclophospamide in combination with myeloablative total body irradiation as conditioning for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study from the Acute Leukemia Working Party
Topics: Acute Disease; Adult; Bone Marrow; Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic | 2023 |
Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT.
Topics: Acute Disease; Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Huma | 2023 |
Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients >45 years-a registry-based study by the Acute Leukemia Working Party of the EBMT.
Topics: Acute Disease; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Human | 2023 |
Intensified conditioning regimen with fludarabine combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in children with high-risk acute leukemia.
Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Child; Cyclophosphamide; Cytarabine; Graft vs | 2023 |
Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cy | 2023 |
Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem | 2020 |
Towards new long-term composite 'Quality of Survival' endpoints.
Topics: Acute Disease; Busulfan; Child; Hematopoietic Stem Cell Transplantation; Humans; Retrospective Studi | 2020 |
[Cutaneous complications following hematopoietic stem cell transplantation].
Topics: Acute Disease; Adolescent; Adult; Allografts; Busulfan; Candidiasis; Chickenpox; Child; Chronic Dise | 2021 |
Permanent diffuse alopecia after haematopoietic stem cell transplantation in childhood.
Topics: Acute Disease; Adolescent; Adult; Alopecia; Busulfan; Child; Child, Preschool; Cross-Sectional Studi | 2017 |
Successful treatment of both acute leukemia and active Crohn's disease after allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and busulfan: a case report.
Topics: Acute Disease; Allografts; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Crohn Di | 2013 |
Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; C | 2013 |
Comparison of intravenous with oral busulfan in allogeneic hematopoietic stem cell transplantation with myeloablative conditioning regimens for pediatric acute leukemia.
Topics: Acute Disease; Administration, Intravenous; Administration, Oral; Adolescent; Antineoplastic Agents, | 2013 |
[Comparing BFA with BuCyA as a myeloablative conditioning regimen for allogeneic stem cell transplantation in acute leukemias].
Topics: Acute Disease; Busulfan; Cyclophosphamide; Cytarabine; Graft vs Host Disease; Humans; Leukemia, Myel | 2014 |
Feasible outcomes of T cell-replete haploidentical stem cell transplantation with reduced-intensity conditioning in patients with myelodysplastic syndrome.
Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Female; Graft vs Host D | 2015 |
Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines.
Topics: Acute Disease; Busulfan; Child; Child, Preschool; Chronic Disease; Cord Blood Stem Cell Transplantat | 2015 |
Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines.
Topics: Acute Disease; Busulfan; Child; Child, Preschool; Chronic Disease; Cord Blood Stem Cell Transplantat | 2015 |
Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines.
Topics: Acute Disease; Busulfan; Child; Child, Preschool; Chronic Disease; Cord Blood Stem Cell Transplantat | 2015 |
Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines.
Topics: Acute Disease; Busulfan; Child; Child, Preschool; Chronic Disease; Cord Blood Stem Cell Transplantat | 2015 |
HLA haploidentical peripheral blood stem cell transplantation using reduced dose of posttransplantation cyclophosphamide for poor-prognosis or refractory leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; G | 2015 |
Subacute hepatic necrosis mimicking veno-occlusive disease in a patient with HFE H63D homozygosity after allogeneic hematopoietic cell transplantation with busulfan conditioning.
Topics: Acute Disease; Adult; Allografts; Busulfan; Diagnosis, Differential; Hematopoietic Stem Cell Transpl | 2015 |
A preclinical acute GVHD mouse model based on chemotherapy conditioning and MHC-matched transplantation.
Topics: Acute Disease; Allografts; Animals; Busulfan; Cyclophosphamide; Disease Models, Animal; Female; Graf | 2016 |
Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Disease-Free Survival; Drug T | 2016 |
A swine model of acute thrombocytopenia with prolonged bleeding time produced by busulfan.
Topics: Acute Disease; Animals; Antineoplastic Agents, Alkylating; Bleeding Time; Busulfan; Disease Models, | 2016 |
Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide.
Topics: Acute Disease; Adolescent; Adult; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Busulfan; Chro | 2008 |
A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Aspergillus; Busulfan; China; Combine | 2009 |
Allogenic bone marrow transplantation with fludarabine/busulfan16 conditioning regimen and dasatinib maintenance therapy for elderly Philadelphia-positive acute/advanced leukemia patients.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bu | 2010 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Prevention of chronic rejection in murine cardiac allografts: a comparison of chimerism- and nonchimerism-inducing costimulation blockade-based tolerance induction regimens.
Topics: Acute Disease; Animals; Bone Marrow Cells; Bone Marrow Transplantation; Busulfan; Chronic Disease; C | 2002 |
Busulfan depletes neutrophils and delays accelerated acute rejection of discordant xenografts in the guinea pig-to-rat model.
Topics: Acute Disease; Animals; Anticoagulants; Busulfan; Graft Rejection; Graft Survival; Guinea Pigs; Hear | 2003 |
Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen.
Topics: Acute Disease; Adolescent; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Disease Progressi | 2003 |
Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (RIST) for patients with haematological malignancies.
Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Chronic Disease; Cladribine; Cyclophosphamide; Dis | 2003 |
Autologous peripheral blood stem cell transplantation in first remission adult acute myeloid leukaemia--an intention to treat analysis and comparison of outcome using a predictive model based on the MRC AML10 cohort.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cl | 2003 |
Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors.
Topics: Acute Disease; Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Chronic Disease; | 2004 |
Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan.
Topics: Acute Disease; Alkylating Agents; Busulfan; Chronic Disease; Drug Therapy, Combination; Female; Huma | 2003 |
Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation--a retrospective analysis.
Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Combined Modality Thera | 2004 |
Busulfan neurotoxicity and EEG abnormalities: a case report.
Topics: Acute Disease; Adult; Alkylating Agents; Bone Marrow Transplantation; Busulfan; Electroencephalograp | 2004 |
Nonmyeloablative stem cell transplantation in patients with ALL and AML results in low nonrelapse mortality despite high rate of infections and GVHD.
Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Contraindications; Cyclosporine; Female; Follo | 2004 |
Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation.
Topics: Acute Disease; Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protoco | 2006 |
Effect of IL-18 and sIL2R on aGVHD occurrence after hematopoietic stem cell transplantation in some Iranian patients.
Topics: Acute Disease; Adolescent; Adult; Biomarkers; Busulfan; Child; Child, Preschool; Cyclophosphamide; F | 2006 |
Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adult; Aged; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Female; Graft S | 2006 |
Long-term outcomes of myeloablation and autologous transplantation of relapsed acute myeloid leukemia in second remission: a British Society of Blood and Marrow Transplantation registry study.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Bone Marrow Transplantation; Busulfan; Cyclopho | 2006 |
[Allogenic transplantation of hemopoietic stem cells in low-intensity regimes in patients with hematological malignancies].
Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Female; Graft vs Host Disease; Hematologic Neoplas | 2007 |
Long-term follow-up of busulfan, etoposide, and nimustine hydrochloride (ACNU) or melphalan as conditioning regimens for childhood acute leukemia and lymphoma.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; C | 2007 |
Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major.
Topics: Acute Disease; Adolescent; beta-Thalassemia; Blood Platelets; Bone Marrow Transplantation; Busulfan; | 2008 |
Characterization of acute graft-versus-host disease following reduced-intensity stem-cell transplantation from an HLA-identical related donor.
Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Aged; Antilymphocyte Serum; Busulfan; Cladribine; Dis | 2008 |
Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Bone Marrow Transplantation; Busulfan; Child; Combine | 1983 |
Preliminary results of high-dose busulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transp | 1984 |
Serial in vitro bone marrow fibroblast culture in human leukemia.
Topics: Acute Disease; Adult; Aged; Bone Marrow Cells; Busulfan; Colony-Forming Units Assay; Culture Techniq | 1983 |
Circulating immune complexes in chronic myeloid leukemia patients at various stages of the disease.
Topics: Acute Disease; Antigen-Antibody Complex; Busulfan; Complement Activating Enzymes; Complement C1q; Hu | 1983 |
Allogeneic bone marrow transplantation for blood cell disorders.
Topics: Acute Disease; Adolescent; Adult; Anemia, Aplastic; Animals; Bone Marrow Transplantation; Busulfan; | 1982 |
Severe esophageal stricture after autologous bone marrow transplant.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; B | 1995 |
Acute cholecystitis after autologous bone marrow transplantation for acute myeloid leukemia.
Topics: Acute Disease; Adult; Bone Marrow Transplantation; Busulfan; Cholecystectomy; Cholecystitis; Cycloph | 1995 |
Peripheral blood stem cells used to augment autologous bone marrow transplantation.
Topics: Acute Disease; Adolescent; Bone Marrow Transplantation; Busulfan; Child; Combined Modality Therapy; | 1994 |
Reconstitution of lymphocyte subsets after peripheral blood stem cell transplantation: two-color flow cytometric analysis.
Topics: Acute Disease; Adolescent; Adult; Blood Component Transfusion; Busulfan; Combined Modality Therapy; | 1994 |
Assessment of the efficacy of purging by using gene marked autologous marrow transplantation for children with AML in first complete remission.
Topics: Acute Disease; Adolescent; Base Sequence; Biomarkers; Bone Marrow Purging; Bone Marrow Transplantati | 1994 |
Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice.
Topics: Acute Disease; Animals; Busulfan; Cell Transplantation; Chronic Disease; Cyclophosphamide; Cytokines | 1994 |
Role of total body irradiation as based on the comparison of preparation regimens for allogeneic bone marrow transplantation for acute leukemia in first complete remission.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transp | 1993 |
Central nervous system granulocytic sarcoma in a patient with essential thrombocythemia.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blast Crisi | 1996 |
Long-term leukemia-free survival after allogeneic marrow transplantation in patients with acute myelogenous leukemia.
Topics: Acute Disease; Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cyclosporine; Disease | 1996 |
Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Topics: Acute Disease; Anemia, Refractory, with Excess of Blasts; Busulfan; Cell Transformation, Neoplastic; | 1996 |
A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood a
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Bone Marrow Transplantati | 1996 |
Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Busulfan; Child; Child, Preschool; Chronic D | 1996 |
Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD.
Topics: Actuarial Analysis; Acute Disease; Adult; Anti-Infective Agents; Bone Marrow Transplantation; Busulf | 1996 |
Autologous transplantation with peripheral blood stem cells collected after granulocyte colony-stimulating factor in patients with acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy | 1996 |
CsA-associated neurotoxicity and ineffective prophylaxis with clonazepam in patients transplanted for thalassemia major: analysis of risk factors.
Topics: Acute Disease; Adolescent; Adrenal Cortex Hormones; Adult; Anticonvulsants; beta-Thalassemia; Blood | 1996 |
Factors which affect the CFU-GM content of the peripheral blood haemopoietic progenitor cell harvests in patients with acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Cyclophosphamide; Fem | 1998 |
Color-flow imaging sonography of portal and hepatic vein flow to monitor fibrinolytic therapy with r-TPA for veno-occlusive disease following myeloablative treatment.
Topics: Acute Disease; Adolescent; Busulfan; Combined Modality Therapy; Cyclophosphamide; Fibrinolytic Agent | 1998 |
Is hydroxyurea leukemogenic in essential thrombocythemia?
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Bone Marrow; Busulfan; Chromosome Aberrations; Chr | 1998 |
Autologous bone marrow transplantation for acute myeloid leukemia using 4-hydroperoxycyclophosphamide-purged bone marrow and the busulfan/etoposide preparative regimen: a follow-up report.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purgin | 1998 |
Clonally unrelated BCR-ABL-negative acute myeloblastic leukemia masquerading as blast crisis after busulphan and interferon therapy for BCR-ABL-positive chronic myeloid leukemia.
Topics: Acute Disease; Adult; Blast Crisis; Bone Marrow; Busulfan; Diagnosis, Differential; Female; Fusion P | 1999 |
Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Bone Marrow Purging; Busulfan; Combined Mod | 1999 |
[Analysis of pulmonary function in leukemia patients after bone marrow transplantation: effects of prior chemotherapy].
Topics: Acute Disease; Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Female; Humans; Immunosuppr | 2000 |
Essential thrombocythemia in young adults: major thrombotic complications and complications during pregnancy--a follow-up study in 68 patients.
Topics: Acute Disease; Adult; Age Factors; Arteriosclerosis; Aspirin; Busulfan; Cohort Studies; Disease-Free | 2000 |
Acute graft-versus-host disease in thalassaemic marrow transplantation with low-dose antithymocyte globulin.
Topics: Acute Disease; Adolescent; Anti-Inflammatory Agents; Antilymphocyte Serum; Bone Marrow Transplantati | 1999 |
Growth and endocrine function in children with acute myeloid leukaemia after bone marrow transplantation using busulfan/cyclophosphamide.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan | 2000 |
Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Prescho | 2000 |
Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; B | 2000 |
Early allogeneic blood stem cell transplantation after modified conditioning therapy during marrow aplasia: stable remission in high-risk acute myeloid leukemia.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Busulfan; Female; | 2001 |
Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation.
Topics: Acute Disease; Adolescent; Adult; Area Under Curve; Busulfan; Drug Administration Schedule; Female; | 2001 |
Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; | 2002 |
[The toxicity of busulphan and cyclophosphamide as the preparative regimen for allogeneic peripheral blood stem cell transplantation].
Topics: Acute Disease; Adult; Busulfan; Cyclophosphamide; Cystitis; Disease-Free Survival; Esophagitis; Fema | 2000 |
Osteochondroma after pediatric hematopoietic stem cell transplantation: report of eight cases.
Topics: Actuarial Analysis; Acute Disease; Bone Neoplasms; Busulfan; Child; Child, Preschool; Cranial Irradi | 2002 |
Allogeneic BMT for infantile acute leukemia: what is the optimal conditioning regimen?
Topics: Acute Disease; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Disease-Free Survival; Etopo | 2002 |
[Determination of serum vitamin B12 in hematologic diseases].
Topics: Acute Disease; Anemia, Pernicious; Busulfan; Hematologic Diseases; Humans; Leukemia; Leukemia, Myelo | 1979 |
Treatment of polycythemia vera.
Topics: Acute Disease; Adult; Aged; Bloodletting; Busulfan; Evaluation Studies as Topic; Female; Humans; Leu | 1979 |
Sudden cardiac tamponade after chemotherapy for marrow transplantation in thalassaemia.
Topics: Acute Disease; Adolescent; Bone Marrow Transplantation; Busulfan; Cardiac Tamponade; Child; Child, P | 1992 |
Treatment of myelodysplastic syndrome with busulfan-cyclophosphamide conditioning followed by allogeneic BMT.
Topics: Acute Disease; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Trans | 1992 |
Marrow transplantation in patients with acute myeloid leukemia.
Topics: Acute Disease; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Drug Administration Schedule | 1992 |
Pretransplant conditioning with busulfan and cyclophosphamide in acute leukemia patients: neurological and electroencephalographic prospective study.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Barbiturates; Bone | 1992 |
Successful treatment of acute myeloid leukemia beyond first remission with autologous bone marrow transplantation using busulfan/cyclophosphamide and unpurged marrow: the British autograft group experience.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; B | 1991 |
Post consolidation therapy for adult patients with acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow | 1991 |
Allogeneic bone marrow transplantation after high-dose busulfan and cyclophosphamide in patients with acute nonlymphocytic leukemia.
Topics: Acute Disease; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Drug Administration Schedule | 1989 |
Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents.
Topics: Acute Disease; Adolescent; Adult; Aged; Alkylating Agents; Antineoplastic Combined Chemotherapy Prot | 1985 |
Letter: Bone marrow damage during treatment of psoriasis with busulphan.
Topics: Acute Disease; Aged; Autopsy; Blood Platelet Disorders; Bone Marrow Diseases; Busulfan; Hematoma; Hu | 1973 |
Abnormalities of platelet function in the myeloproliferative disorders.
Topics: Acute Disease; Adult; Blood Coagulation Tests; Blood Platelet Disorders; Busulfan; Female; Humans; L | 1972 |
Lung biopsy in the acutely ill--when and how? Clinical conference in pulmonary disease.
Topics: Acute Disease; Biopsy; Busulfan; Exudates and Transudates; Humans; Leukemia, Myeloid; Lung; Male; Mi | 1972 |
[Acute hemopericardium due to acute thrombocytopenia developing during Busulphan treatment of polycythemia vera].
Topics: Acute Disease; Adult; Anemia, Aplastic; Busulfan; Cardiac Tamponade; Humans; Male; Pericardial Effus | 1973 |
Acute megakaryocytic myelofibrosis. Case report of an unusual myeloproliferative syndrome.
Topics: Acute Disease; Adrenal Gland Neoplasms; Autopsy; Bone Marrow; Bone Marrow Cells; Busulfan; Female; H | 1974 |
Polycythemia vera terminating in acute myelogenous leukemia with fibrosis of bone marrow: case report.
Topics: Acute Disease; Aged; Busulfan; Female; Humans; Leukemia, Myeloid; Polycythemia; Primary Myelofibrosi | 1967 |
Cytogenetic remission in acute transformation of chronic granulocytic leukaemia.
Topics: Acute Disease; Aged; Aneuploidy; Bone Marrow Diseases; Busulfan; Cell Transformation, Neoplastic; Ch | 1969 |
Blastic crisis of chronic myelogenous leukaemia.
Topics: Acute Disease; Adult; Antineoplastic Agents; Busulfan; Chronic Disease; Female; Hematopoiesis; Human | 1969 |